2021
DOI: 10.1186/s11671-021-03626-8
|View full text |Cite
|
Sign up to set email alerts
|

Biocompatible FePO4 Nanoparticles: Drug Delivery, RNA Stabilization, and Functional Activity

Abstract: FePO4 NPs are of special interest in food fortification and biomedical imaging because of their biocompatibility, high bioavailability, magnetic property, and superior sensory performance that do not cause adverse organoleptic effects. These characteristics are desirable in drug delivery as well. Here, we explored the FePO4 nanoparticles as a delivery vehicle for the anticancer drug, doxorubicin, with an optimum drug loading of 26.81% ± 1.0%. This loading further enforces the formation of Fe3+ doxorubicin comp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 50 publications
0
1
0
Order By: Relevance
“…Example of these includes, DOXIL® for ovarian cancer (secondary to platinumbased therapies) 18 and HIV-associated Kaposi's sarcoma (secondary to chemotherapy), multiple myeloma (secondary); Abraxane® for advanced non-small cell lung cancer, metastatic breast cancer, and pancreatic cancer, VYXEOS® for acute myeloid leukemia, Hensify® for locally-advanced squamous cell carcinoma, Resovist® as a magnetic resonance imaging contrast agent and the list further increases with the total of more than 50 approved nanomedicine for clinical use. 15 While signicant efforts have been dedicated to engineering synthetic and biomimetic nanomedicine against cancer, 5,[7][8][9]16,[19][20][21][22][23][24][25][26][27] the studies related to the effect of NPs on enzyme receptor biochemical activity have been given less attention to envisioning its possible impact on infectious disease and immune modulation.…”
Section: Introductionmentioning
confidence: 99%
“…Example of these includes, DOXIL® for ovarian cancer (secondary to platinumbased therapies) 18 and HIV-associated Kaposi's sarcoma (secondary to chemotherapy), multiple myeloma (secondary); Abraxane® for advanced non-small cell lung cancer, metastatic breast cancer, and pancreatic cancer, VYXEOS® for acute myeloid leukemia, Hensify® for locally-advanced squamous cell carcinoma, Resovist® as a magnetic resonance imaging contrast agent and the list further increases with the total of more than 50 approved nanomedicine for clinical use. 15 While signicant efforts have been dedicated to engineering synthetic and biomimetic nanomedicine against cancer, 5,[7][8][9]16,[19][20][21][22][23][24][25][26][27] the studies related to the effect of NPs on enzyme receptor biochemical activity have been given less attention to envisioning its possible impact on infectious disease and immune modulation.…”
Section: Introductionmentioning
confidence: 99%